Journal of Clinical Oncology

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

I Ivan Marquez-Rodas C Caroline Dutriaux P Philippe Saiag L Luis de la Cruz Merino E Eduardo Castanon Alvarez (Clínica Universidad de Navarra, Madrid, Spain) C Caroline Robert J Juan F. Rodríguez-Moreno A Ana Arance (Hospital Clinic Barcelona and IDIBAPS, Barcelona, Spain) P Pablo Cerezuela-Fuentes H Henri Montaudie (Department of Dermatology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France) M Miguel F. Sanmamed M María González-Cao J Julie Charles M María Pilar López Criado A Alfonso Berrocal E Enrique de Miguel E Elisa Funck-Brentano S Sorilla Prey (University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312) M Mᵃ Carmen Álamo de la Gala I Ignacio Melero J Jose Antonio Avilés-Izquierdo R Ruth Román B Beatriz Garcia-Pelaez S Sonia Rodriguez Z Zuzana Jirakova Trnkova M Marisol Quintero S Sonia Macia (SMED Clinical Research, Alicante, Spain) M Marya F. Chaney (Merck & Co, Inc., Rahway, NJ) S Stéphane Dalle
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 43, Issue 25
Published September 01, 2025
Pages 2840-2840
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (29)

I

Ivan Marquez-Rodas

C

Caroline Dutriaux

P

Philippe Saiag

L

Luis de la Cruz Merino

E

Eduardo Castanon Alvarez

Clínica Universidad de Navarra, Madrid, Spain

C

Caroline Robert

J

Juan F. Rodríguez-Moreno

A

Ana Arance

Hospital Clinic Barcelona and IDIBAPS, Barcelona, Spain

P

Pablo Cerezuela-Fuentes

H

Henri Montaudie

Department of Dermatology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France

M

Miguel F. Sanmamed

M

María González-Cao

J

Julie Charles

M

María Pilar López Criado

A

Alfonso Berrocal

E

Enrique de Miguel

E

Elisa Funck-Brentano

S

Sorilla Prey

University of Bordeaux, Inserm, Bordeaux Institute of Oncology, UMR 1312

M

Mᵃ Carmen Álamo de la Gala

I

Ignacio Melero

J

Jose Antonio Avilés-Izquierdo

R

Ruth Román

B

Beatriz Garcia-Pelaez

S

Sonia Rodriguez

Z

Zuzana Jirakova Trnkova

M

Marisol Quintero

S

Sonia Macia

SMED Clinical Research, Alicante, Spain

M

Marya F. Chaney

Merck & Co, Inc., Rahway, NJ

S

Stéphane Dalle

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001